These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acquired Resistance to KRAS Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704 [TBL] [Abstract][Full Text] [Related]
5. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474 [TBL] [Abstract][Full Text] [Related]
6. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505 [TBL] [Abstract][Full Text] [Related]
7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer. Lee C; Jiang ZK; Planken S; Manzuk LK; Ortiz R; Hall M; Noorbehesht K; Ram S; Affolter T; Troche GE; Ihle NT; Johnson T; Ahn Y; Kraus M; Giddabasappa A Mol Cancer Ther; 2023 Jul; 22(7):891-900. PubMed ID: 37186518 [TBL] [Abstract][Full Text] [Related]
11. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747 [TBL] [Abstract][Full Text] [Related]
12. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS Hoshiyama H Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617 [TBL] [Abstract][Full Text] [Related]
14. Loss of wild type KRAS in KRAS Liu Y; Gao GF; Minna JD; Williams NS; Westover KD Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697 [TBL] [Abstract][Full Text] [Related]
15. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P; Solomon M; Li LS; Hansen R; Rosen N Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430 [TBL] [Abstract][Full Text] [Related]